Keloid disease (KD) is a common fibroproliferative disorder of unknown etiopathogenesis. Its unique occurrence in human skin and lack of animal models pose challenges for KD research. The lack of a suitable model in KD and overreliance on cell culture has hampered the progress in developing new treatments. Therefore, we evaluated the effect of two promising candidate antifibrotic therapies: ( À )-epigallocatechin-3-gallate (EGCG) and plasminogen activator inhibitor-1 (PAI-1) silencing in a long-term human keloid organ culture (OC). Four millimeters of air-liquid interface (ALI) keloid explants on collagen gel matrix in serum-free medium (n ¼ 8 cases) were treated with different modalities (EGCG treatment; PAI-1 knockdown by short interfering RNA (siRNA) and application of dexamethasone (DEX) as control). Normal skin (n ¼ 6) was used as control (only for D0 keloid-untreated comparison). Besides routine histology and quantitative (immuno-) histomorphometry, the key phenotypic and growth parameters of KD were assessed. Results demonstrated that EGCG reduced keloid volume significantly (40% by week 4), increased apoptosis (Z40% from weeks 1 to 4), and decreased proliferation (r17% in week 2). EGCG induced epidermal shrinkage, reduced collagen-I and -III at mRNA and protein levels, depleted 98% of keloid-associated mast cells, and reduced the percentage of both cellularity and blood vessel count by week 4. Knockdown of PAI-1 significantly reduced keloid volume by 28% in week 4, respectively, and reduced collagen-I and -III at both mRNA and protein levels. As expected, DEX increased keloid apoptosis, decreased keloid proliferation, and collagen synthesis, but induced connective tissue growth factor overexpression. In conclusion, using keloid OC model, we provide the first functional evidence for testing candidate antifibrotic compounds in KD. We show that EGCG and PAI-1 silencing effectively inhibits growth and induces shrinkage of human keloid tissue in situ. Therefore, the application of EGCG, PAI-1 silencing, and other emerging compounds tested using this model may provide effective treatment and potentially aid in the prevention of recurrence of KD following surgery. Keloid disease (KD) is a benign hyperproliferative dermal disease of unknown etiopathogenesis with ill-defined treatment, 1 which is unique to humans. 2 KD can arise following an abnormal wound healing process in genetically susceptible individuals. 2 The hallmark of KD is excessive deposition of extracellular matrix (ECM) in the dermis. 3 The lack of an animal model that can truly mimic human KD in vivo condition imposes limitations when investigating functional activities of potential therapeutic agents in treating KD. 4, 5 However, these models have failed to provide the essential components of skin tissue that occur in vivo, such as mature ECM, blood vessels, inflammatory cells, and intrinsic and extrinsic biochemical interactions. Therefore, the ultimate aim of this study was to determine the applicability of recent research findings in existing in vitro keloid models to our recently developed keloid organ culture (OC) model. 6 OC of human skin has already been extensively utilized as a useful method for investigating skin biology. 7,8 Therefore, we reported the development of a serum-free ex vivo model of human KD, in which keloid tissue is organ cultured at the
Keloid disease (KD) is a benign hyperproliferative dermal disease of unknown etiopathogenesis with ill-defined treatment, 1 which is unique to humans. 2 KD can arise following an abnormal wound healing process in genetically susceptible individuals. 2 The hallmark of KD is excessive deposition of extracellular matrix (ECM) in the dermis. 3 The lack of an animal model that can truly mimic human KD in vivo condition imposes limitations when investigating functional activities of potential therapeutic agents in treating KD. 4, 5 However, these models have failed to provide the essential components of skin tissue that occur in vivo, such as mature ECM, blood vessels, inflammatory cells, and intrinsic and extrinsic biochemical interactions. Therefore, the ultimate aim of this study was to determine the applicability of recent research findings in existing in vitro keloid models to our recently developed keloid organ culture (OC) model. 6 OC of human skin has already been extensively utilized as a useful method for investigating skin biology. 7, 8 Therefore, we reported the development of a serum-free ex vivo model of human KD, in which keloid tissue is organ cultured at the air-liquid interface (ALI). 6 This keloid OC model has several advantages: first, keloid explants remain viable in culture for up to 6 weeks (without major deterioration of tissue morphology); second, the maintenance of keloid cellular and molecular microenvironments, which are capable of exerting their biochemical and molecular effects on the tissue, allow examination of KD pathophysiology in situ; third, antifibrotic agents and gene silencing using RNA interference (RNAi) technology can be used to understand the cellular and molecular interactions in both the epidermis and dermis that maintain keloid tissue growth; and, finally, novel candidate antikeloid agents can be preclinically tested in this OC system under clinically relevant ex vivo conditions. 6 Using recent advances in keloid 9 and normal skin OC models, 8 the keloid OC model permits the growth of 4 mm explants in a collagen matrix at the ALI in supplemented William's E (WE) medium for up to 6 weeks. 6 In this model, dexamethasone (DEX) treatment serves as a robust positive control that inhibits keloid tissue growth. 6 While currently, corticosteroids are the first-line pharmacological therapy for the management of KD, there is no effective treatment identified to date that can completely eradicate as well as reduce recurrence of KD. 1 Therefore, there is an urgent need for the development of effective, novel, antikeloid therapies that complement surgical excision of keloid tissue.
One promising new antikeloid agent, which awaits clinical evaluation, is ( À )-epigallocatechin-3-gallate (EGCG). 4, 10 This has been previously tested in human-derived keloid fibroblasts transplanted onto nude mice, and showed decreased collagen production and subsequent reduction of keloid. 4, 10 Reportedly, another important factor for excessive fibrogenesis in KD is the overexpression of plasminogen activator inhibitor-1 (PAI-1) in fibroblasts, which elevates collagen production. 11 Knocking down PAI-1 using either short interfering RNA (siRNA) inhibited collagen synthesis in keloid fibroblasts. 12 The aim of this study was to validate EGCG and PAI-1 silencing in an actual human keloid OC model to generate optimal, clinically relevant preclinical evidence whether or not these antikeloid strategies deserve further clinical testing. EGCG treatment and PAI-1 knockdown in situ were compared with DEX as a positive control. The results showed that EGCG treatment and PAI-1 silencing both effectively inhibit growth and induce shrinkage of human keloid tissue in situ.
MATERIALS AND METHODS Patient Recruitment and Preparation of Keloid OC
Only patients presenting with features typical of KD, with no previous intralesional treatment, 3, 6 were recruited for this study. In addition, following routine therapeutic excision of keloid scars, each sample underwent independent additional histopathological confirmation of diagnosis of their keloid, which was performed by an experienced dermatopathologist.
All keloid patients recruited gave full informed consent in our ethically approved study. Eight keloid cases and six control subjects (normal skin in an individual with no personal or family history of KD) with an age range of 16-43 years, of multiple ethnicities, were included in this study (Supplementary Table S1 ). After surgery, excised keloid tissue were washed and soaked in Hank's buffer (Sigma-Aldrich, Dorset, UK) for 30 min. Then, 4-mm punch biopsies (explants or OC) were cut and embedded in collagen gel matrix on ALI and maintained with serum-free, supplemented WE medium (Sigma-Aldrich), as described previously 6 ( Figure 1a) . Media with or without treatment were changed every third day.
DEX and EGCG Administration DEX and EGCG (Sigma-Aldrich) were dissolved in dimethyl sulfoxide. Four millimeters of ALI keloid OCs were maintained in serum-free, supplemented WE media containing either 50 mg/ml DEX, as positive control, or 100 mg/ml EGCG up to 4 weeks. Dimethyl sulfoxide/WE-supplemented media were used as vehicle control. Media were changed every third day with fresh media with or without treatment. Tissue and media were collected at defined time points as described in Figure 1b .
Predesigned PAI-1 siRNA for Knockdown of PAI-1 in the Keloid OC Model Predesigned PAI-1 siRNA was purchased from Ambion (Paisley, UK) Applied Biosystems (Warrington, UK) ( Table 1) . Keloid OC (4-mm) punch biopsies were transiently transfected with PAI-1 siRNA and scrambled siRNA (250 and 500 nm) using siPORT NeoFX Transfection agent (Applied Biosystems) according to the manufacturer's instructions.
In one set of experiment, media were replaced every 72 h with fresh WE serum-free, supplemented media containing the same amount of siRNA, until 4 weeks. In the second set of experiment, after first transfection with PAI-1 siRNA, the media were replaced every 72 h with fresh media until 4 weeks, without siRNA, to analyze the persistence of PAI-1 siRNA. Tissue was collected at days 0, 1, and 3, and weeks 1-4 in RNAlater, formalin, and in the culture media for analysis Figure 1b .
Transfection of PAI-1/Scrambled siRNA in Keloid OC Using siPORT NeoFX The protocol was followed according to the manufacturer's instructions. Briefly, for preparation of siRNA and reagent dilutions, a sterile tube (round or V-bottom) was used. When possible, master mix was prepared to minimize variability. siPORT NeoFX Transfection agent (3 ml) was diluted in Opti-MEM I medium (50 ml) and incubated at room temperature for 10 min. Then, PAI-1 (250 and 500 nm) or Scrambled (250 and 500 nm) siRNA were diluted into Opti-MEM I medium (50 ml). Thereafter, the diluted siPORT NeoFX Transfection Agent and diluted siRNA were combined. Subsequently, this Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al was gently mixed by pipetting up and down or flicking the tube a few times, before it was incubated for 10 min at room temperature to allow transfection complexes to form. After incubation, siRNA/siPORT NeoFX Transfection Agent transfection complexes was dispensed into wells of the keloid OC containing 500 ml of (final volume) media and the keloid OC culture plates were incubated at 371C/5% CO 2 . The transfection was then repeated every 72 h in the keloid OC for up to 4 weeks.
Cytotoxicity and Viability/Metabolic Activity Assays
The cytotoxicity using lactate dehydrogenase (LDH) assay and viability/metabolic activity using methylthiazol tetrazolium (MTT) assay (Roche, West Sussex, UK) were Apoptosis and Ki-67 Detection In Situ Terminal dUTP nick-end labeling (DeadEnd TUNEL; Promega, Southampton, UK) was used as a marker for apoptosis combined with fluorescence immunohistochemistry of cell proliferation marker Ki-67 as described previously. 6, 13 Histology Tissue sections were stained for morphological analysis with hematoxylin and eosin using standard methodology. 3, 6 Micrographs were captured using Olympus BX51 (Olympus, Essex, UK) microscope. For cellularity/inflammation and CD31 þ cell analysis, percentage was calculated relative to day 0 in the dermis from four independent patients.
Immunofluorescence
A range of markers listed in Supplementary Table S2 were localized on paraffin sections (5 mm). Micrographs for immunofluorescence (IF) were captured using confocal microscope (Zeiss LSM 510META, Hertfordshire, Germany). Quantitative immunohistomorphometry was carried out as described previously. 14 Collagen I and III ELISA Quantitative collagen I and III protein expression secreted in the media, collected from treated keloid OC and vehicletreated control, were measured using capture sandwich and indirect ELISA following a protocol that was optimized previously. 3, 6 RNA Extraction, cDNA Synthesis, and qRT-PCR Keloid OC tissue biopsies were collected at different time points (Figure 1b ) post-treatment in RNAlater (Applied Biosystems). RNA extraction was performed using RNeasy mini kit (Qiagen, Crawley, UK). 15 Subsequently, 1 mg mRNA was converted to cDNA using qScript cDNA Synthesis kit (Quanta BioSciences, Gaithersburg, MD, USA) 15 Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was carried out with standard protocol 15 using a number of gene-specific primers (Supplementary Table S3 ).
Shrinkage of Keloid Volume, Epidermal Thickness, Reduced Cellularity, and Vascularity Keloid shrinkage assay, epidermal thickness shrinkage, cellularity, and vascularity were assessed by means of histology and immunohistochemistry as described previously. 6 
Statistical Analysis
Each experiment was performed independently for two to three times. Data were expressed as mean ± standard error (s.e.m.). Statistical evaluation of data was performed using ANOVA in SPSS 16.0 software program (SPSS Inc., Chicago, IL, USA). Differences with Po0.05 were considered significant. Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al at week 1 onwards (Figure 3d) . Surprisingly, DEX showed no significant changes in the secreted collagen I and III at the protein level (Figures 3e and f) . In contrast, collagen I immunoreactivity was also markedly decreased ( Figure 4 ) in EGCG-treated OC. In contrast, overall, EGCG reduced intrakeloid collagen synthesis more efficiently than DEX.
RESULTS

EGCG is Cytotoxic and Inhibits Collagen Production in
EGCG Downregulates Transcription of Major FibrosisAssociated Pathways
As shown in Figure 3a , transcription of the investigated fibrotic-associated genes (vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP 2 and 9), and TGF-b2), which have been implicated in KD pathobiology, 16, 17 were inhibited by EGCG treatment as measured by qRT-PCR ( Figure 3a ) compared with the vehicle-treated control. Similar effects on major fibrosis-associated pathways were also seen with DEX ( Figure 3b ). Interestingly, we also measured the expression profile of TGF-bII at the protein level, in keloid OC, and the results showed visible reduction in TGF-bII expression at week 1 and week 4 treatment with EGCG when compared with the control group (Figure 4a ).
DEX Upregulates CTGF Expression in Keloid OC, While EGCG Downregulates CTGF Connective tissue growth factor (CTGF) is a recognized key growth factor during wound healing and in KD pathobiology. 18, 19 Hence, the effect of EGCG and DEX on CTGF expression was also investigated. Interestingly, CTGF gene expression was significantly downregulated by EGCG treatment (Figure 3a ). In contrast, there was a significant (Pr0.01) overexpression of CTGF mRNA in DEX-treated keloid OC compared with the vehicle-treated control (Figure 3b ), which also correlated with the in situ protein level (Figure 4b ). Thus, glucocorticoid treatment can indeed enhance the in situ expression of a major keloid-promoting growth factor, while EGCG has the opposite effect.
EGCG Depletes Mast Cells
As shown in Figure 5a , mast cells are shown to be associated with keloid. In our keloid OC model, treatment with EGCG significantly decreased mast cell numbers (Pr0.01), and a 93-98% depletion of mast cells were observed by week 4 in comparison to the vehicle-treated control. 
EGCG Stimulates Intrakeloid Apoptosis and Inhibits Proliferation
Reduction of mast cell numbers may reflect the pronounced level of apoptosis in keloid OC observed after EGCG treatment (Pr0.03), starting at week 1 and persisting up to week 4. The increased percentage of apoptotic cells compared with the vehicle control was evidenced by quantitative caspase-9, active caspase-3 (Figures 6a and b) , and TUNEL immunohistomorphometry (Figure 6c ). Furthermore, a sharp decline in proliferation (Ki-67 þ cells) was detected in the EGCG-treated OC by week 4 (Po0.05) compared with vehicle-treated controls (Figure 6c ). These proapoptotic effects of EGCG were only slightly less impressive as those seen in the positive control, that is, DEX-treated keloid OC (Figures 6a-c) .
EGCG Induces Keloid Shrinkage in OC and Reduces Epidermal Thickness, Percentage of both Cellularity, and Blood Vessel Density To evaluate the therapeutic potential of EGCG in the treatment of KD, the weight of keloid OC was measured weekly for up to 4 weeks post-treatment. Results showed visible shrinkage of keloid weight reflected by significant (P ¼ 0.01) reduction of keloid OC weight by 28% at week 3 and by 39% at week 4 compared with the vehicle-treated control (Figures  7a and b) . H&E staining and quantitative CD31 analyses showed that EGCG reduced the percentage of both cellularity/inflammation and blood vessel (CD31 þ cells) immunoreactivity up to 46% and 273% at day 2, respectively, relative to day 0 (Figures 8a-d) . Furthermore, there was a Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al significant (Po0.05) reduction in the epidermal thickness upon EGCG treatment at week 2 (28% reduction) reaching 59% reduction in week 4, relative to the vehicle control group (Figure 8e ). The reduction in cellularity/inflammation and vascularity percentage was significant (Pr0.01) compared with the vehicle-treated control. Keloid size, cellularity/inflammatory, and blood vessels were also suppressed by DEX treatment as reported previously in keloid OC; 6 however, it appears (data comparison between EGCG from this study and DEX-treated groups from the previously reported study 6 ) that the effect of EGCG is more efficient than DEX.
PAI-1 Silencing Reduces Keloid Volume and Collagen Synthesis
Knockdown efficiency analysis revealed successful reduction of PAI-1 gene a day after transfection with an average reduction of 60% at 250 nM PAI-1 siRNA concentration, as opposed to the average reduction of 10% using a 500 nM concentration (Figure 9a ). More importantly, PAI-1 siRNA gene silencing visibly suppressed the expression of PAI-1 protein in keloid OC from week 1 to week 4 ( Figure 9b ). This represents the first successful gene knockdown in an intact human keloid tissue in situ and provides proof-of-principle that gene silencing in the current keloid OC model.
After PAI-1 siRNA administration, a significant difference in cytotoxicity and viability/metabolic activity was observed up to week 4, with the 500 nM compared with the vehicletreated control (scrambled oligos). However, 250 nM siRNA induced a significant increase of cytotoxicity at week 2, and only a slight change was observed with the viability/metabolic activity (at week 4) (Figures 10a and b) .
The transcriptions of important PAI-1 downstream target genes, including collagen I at mRNA (Figure 10c ), protein level (Figure 10d) , and collagen III at mRNA level (Figure 11a) , were effectively reduced a day post-transfection (250 nM siRNA) by an average of 54% and 30%, respectively. By qRT-PCR, PAI-1 knockdown had no statistically significant (PZ0.05) effect on the transcription of major profibrotic pathway players (Figure 11a ). In addition, PAI-1 silencing significantly reduced collagen-I (Figure 11b ) and -III (Figure 11c ) protein levels as well. This corresponded well to a noticeable decrease in the hyalinized collagen bundles in tissue sections (up to 4 weeks) in PAI-1-silenced keloid OC (Figure 11d ). Interestingly, no major morphological differences in the tissue architecture were observed in the scrambled oligo-treated control keloid OC (Figure 11d ). As PAI-1 siRNA transfection at the 250 nM concentration was more effective than the 500 nM concentration; hence, most of Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al the tissue analyses after PAI-1 siRNA treatment were conducted only with the 250 nM PAI-1 siRNA-treated group. Keloid shrinkage assay demonstrated a significant decrease of keloid volume by 28%, after 4 weeks (Figures 7a and b) . However, no obvious differences in comparison to control was observed in the caspase-9 and -3 (Figures 6a and b) , TUNEL, and proliferation (Ki-67) (Figure 6c) analyses. Therefore, the keloid shrinkage induced by PAI-1 silencing appears to result primarily from its effects on collagen production in situ.
DISCUSSION
Here, we present a novel assay for the long-term, serum-free OC of native human keloid tumors within their natural tissue habitat. This explicitly includes keloid-associated epidermis, blood vessels, mast cells, and perilesional stroma, all of which have been implicated in the pathobiology of KD. Using a unique keloid OC model, 6 we provide the first functional evidence that EGCG and PAI-1 silencing effectively inhibit growth and induce shrinkage of human keloid tissue in situ. Specifically, EGCG reduced keloid size, intrakeloid proliferation, collagen-I and -III production, mast cell numbers, blood vessel, and the expression of major profibrotic factors, while it increased intrakeloid apoptosis and induced epidermal shrinkage. PAI-1 knockdown in keloid OC, which represents the first successful gene silencing in intact human keloid tissue, also induced keloid tissue shrinkage, largely via its inhibitory effect on collagen Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al synthesis. Therefore, it deserves systematic testing to establish whether application of EGCG and/or PAI-1 silencing before and after surgical excision can reduce size of KD as well as prevent its recurrence in combination with surgery.
In addition, this study shows that our recently reported assay system for the long-term, serum-free OC of native human keloid, within its natural tissue habitat, is optimally suited for pathophysiological/mechanistic keloid research that would otherwise only be possible in (non-existing) Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al Ex vivo keloid organ culture evaluates potential antifibrotic agents F Syed et al transgenic animal model or keloid cell culture. 6 Furthermore, this novel, clinically highly relevant assay enables direct assessment of innovative and promising antikeloid therapies at the preclinical level (compared with DEX as a positive control) before proceeding to the clinical trial stages. Glucocorticoids are still the gold standard pharmacological therapy for the management of KD. 20 Thus, here we have used DEX as a positive control. DEX decreased both collagen-I and -III at mRNA levels; however, there was no significant effect at protein levels. The reason for this may be that collagen-I and -III mRNA were degraded by DEX, whereas there may not have been any effect at the protein level. DEX, however, induces apoptosis in many cell types and (on the basis of in vitro studies) is thought to induce keloid regression through suppression of VEGF and fibroblast proliferation. 21 In addition, DEX inhibits MMPs in ocular fibroblasts. 22 While DEX downregulated the expression of profibrotic pathways, including VEGF, TGFb2 at mRNA level in ex vivo keloid OC system, DEX also induced CTGF overexpression. This is in line with previous in vitro reports that had studied cultured murine fibroblast and hepatocytes. 23, 24 Thus, DEX also exerts an undesirable effect by stimulating the gene and protein expression of a putative keloidpromoting CTGF, as elevated CTGF levels correlate with the increased matrix deposition, and formation of tissue fibrosis. 18, 19 Our findings may offer a reasonable explanation for the high recurrence rate of keloid after glucocorticoid treatment. 1 Therefore, the current keloid OC model appears to be capable of detecting both desired and potentially undesirable effects of candidate antikeloid agents at the preclinical level. Here, we used 50 mg/ml DEX, which was derived from our previous in vitro work on fibroblasts using real-time cell analyzer on a microelectronic sensory array. 25 Therefore, from this monoculture experiments, we extrapolated the optimal concentration for the keloid OC. Taken together, the prolonged administration of DEX provides a sensitive testing system for checking the effects of candidate antikeloid agents on the expression of important signaling pathways relevant to keloid pathobiology. Such an effect of DEX observed in the OC model also emphasizes that DEX deserves systematic exploration in future KD management.
The increased recurrence of keloid, despite the availability of different treatments, has driven research to identify and investigate novel therapeutic modalities. One of these narrative modalities is green tea extract, EGCG, which has been extensively studied as a therapeutic compound for several cancers. 26 Recent work on EGCG in cell culture proposed a potential use of EGCG as an antikeloid treatment. 4, 10 Our OC data support the view that these prior observations with EGCG are of major clinical interest. In addition, we show that EGCG downregulates multiple profibrotic pathways (including PDGF, CTGF, MMPs (2 and 9), collagen, PI-3K, and STAT3). This is supported with the documented inhibitory effects of EGCG on tumour invasion, metastasis, and angiogenesis, both in vitro and in vivo. 26 These effects observed here may limit the growth and possibly the recurrence of KD. Our new keloid OC data suggest that intralesional injection of EGCG is an attractive candidate to limit the growth, and possibly the recurrence of KD in vivo. It has been shown that administration of EGCG in animal trials induced less side effect and is welltolerated at minimum doses depending on the route of administration (500 mg/kg orally and 0.09% (1.8 mg/kg) EGCG intradermally). 27, 28 The strong association of mast cells with fibrosis has been well established in several conditions, including KD. 29 EGCG can attenuate mast cell-induced collagen production and fibroblast proliferation in keloid in vitro, coculture models through STAT3 and PI-3K pathways. 10 That EGCG almost depleted mast cell numbers in the current keloid OC model confirms the potent impact of EGCG on mast cells and raises the possibility that the EGCG-induced reduction of intrakeloid collagen production may have occurred at least, in part, via downregulation of STAT3 and PI-3K.
Gene transfection using RNAi in human keloid cells either using cell culture or coculture was made possible with siRNA, 12 as well as in organotypic normal skin model. 30 However, there have been no studies to date investigating the applicability of RNAi to silence a target gene in a keloid OC model, to evaluate its efficiency as a potential antikeloid treatment in situ. Here, we demonstrate that satisfactory knockdown efficiency of PAI-1 can be achieved even in keloid OC, suggesting that other keloid-promoting genes may also be silenced in situ and no doubt encourages further investigation into the effect of target gene knockdown both for obtaining better mechanistic insights into KD pathobiology in situ and for exploring novel candidate antikeloid therapies. PAI-1 siRNA was sustained for at least 5 days in our keloid OC model, as revealed by decreased PAI-1 mRNA expression (data not shown). Importantly, PAI-1 knockdown was efficient at a lower concentration (250 nM) in OC model but a higher concentration (500 nM) showed cytotoxicity and increased cell death. This may be due to offtarget effects, as an increased concentration of siRNA may compromise the specificity of the siRNA target. The use of RNAi technology in keloid OC may allow us to investigate the direct role of target genes in the epidermis/dermis without the difficulties imposed in an animal model, as animals do not develop KD.
The shrinkage of keloid OC and collagen deposition defined in this study indicates that the inhibitory effect of PAI-1 siRNA could be used as potential antikeloid treatment in the future. Such an inhibitory effect on collagen synthesis was also confirmed previously in an in vitro keloid model. 12 Despite the link between PAI-1 and apoptosis, 31 no significant changes were observed in our OC model. This could be explained by the low siRNA concentration used (250 nM). Nonetheless, DEX appears to be more effective than EGCG and PAI-1 siRNA in its ability to induce apoptosis, and cytotoxicity in situ. On the other hand, reduction of collagen synthesis and shrinkage of keloid OC were more efficient with EGCG and PAI-1.
In the initial experiments at both the molecular and cellular level, we also compared proliferation rate and the expression pattern of fibrotic markers (without any treatment, on day 0 cells or tissue samples) in keloid vs normal skin vs extralesional tissue/primary fibroblasts (tissue collected away from the keloid lesion, from the same keloid patients, denoted as extralesional). Interestingly, we did not find a statistically significant difference in proliferation and in fibrotic markers expression pattern, between extralesional (same ethnic groups as keloid) vs normal skin primary fibroblasts, suggesting that extralesional tissue/primary fibroblasts behave similar to normal skin tissue/primary fibroblasts obtained from white ethnic group (our unpublished data). Hence, in this study, we excluded extralesional tissue, and compared the expression of collagen and PAI-1 between normal and keloid tissue at D0 (untreated only).
Given the unexpected, potentially undesired stimulatory effects of DEX on CTGF expression, which may be countered by EGCG, suggest that combination therapies that include EGCG and PAI-1 antagonists, alone or in conjunction with glucocorticoids, are promising novel antikeloid agents. These can potentially be used to reduce keloid volume before primary surgery to reduce keloid recurrence after excision. The clinical application of these potential compounds may involve the administration of EGCG or blockade of PAI topically and/or via an intralesional injection. The most ideal delivery format likely will be based on the successful penetration of the aforementioned topical administration into the dense keloid scar tissue. It is envisaged that for the larger lesions, a combination of surgical debulking as well as topical application or intralesional injection will be considered. The timing of combination therapy will be borne out by future clinical trials, evaluated by comparing topical and/or intralesional injection to keloid lesions pre-and postsurgical excision.
